Clinical trials: Endocrine Disorder
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Trial name
- NCT07570966
- Testing
- ERW316, Fulvestrant, Letrozole
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Healthy Volunteer, Type 2 Diabetes
A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477
This study is designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6799477 following once daily oral administration for 2 weeks in healthy volunteers (Part 1) and in Type 2 diabetes…
- Trial name
- NCT02164266
- Testing
- RO6799477
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
This is a multicenter, open-label study of safety and efficacy of Quisinostat in combination with Paclitaxel + Carboplatin chemotherapy in patients with metastatic or locally advanced epithelial ovarian cancer, primarily…
- Trial name
- NCT02948075
- Testing
- Quisinostat, Paclitaxel, Carboplatin
- Where
- 6 sites in Russia
- Volunteers
- 31 people
- Sponsor
- NewVac LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric…
- Trial name
- NCT02773381
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.
The aim of this study is to assess how safe the study drug is and how well a participant tolerates it after a single oral (taken by mouth) dose.
- Trial name
- NCT03617081
- Testing
- NNC0113-2023
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the…
- Trial name
- NCT01928381
- Testing
- AZD5213 + pregabalin, pregabalin capsules
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin
The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.
- Trial name
- NCT02685345
- Testing
- DS-8500a 25 mg, DS-8500a 75 mg
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Albuminuria
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein…
- Trial name
- NCT00136773
- Testing
- amlodipine/benazepril
- Volunteers
- 332 people
- Sponsor
- Novartis
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Obesity, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
- Trial name
- NCT06305351
- Testing
- K-757 and K-833 QD, K-757 and K-833 BID
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TriGemX Bio, Inc.
Diabetes Mellitus, Type 2
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants…
- Trial name
- PIONEER START (NCT05444153)
- Testing
- Semaglutide, Empagliflozin
- Sponsor
- Novo Nordisk A/S
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 2
A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.
- Trial name
- NCT01159938
- Testing
- Lispro
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Down Syndrome, Edwards Syndrome
Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies
This study will evaluate the clinical performance of massively parallel sequencing (MPS) using the MaterniT21 PLUS LDT in the detection of fetal aneuploidy in circulating cfDNA extracted from a maternal blood sample obtained from…
- Conditions
- Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome
- Trial name
- NCT02226315
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sequenom, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.